ESTRO 2024 - Abstract Book

S1623

Clinical - Lung

ESTRO 2024

trachea and mainstem bronchus of 75Gy EQD 2,3 , 100Gy EQD 2,3 and 110Gy EQD 2,3 , respectively, had to be respected. The secondary endpoints were local control (LC), disease-free survival (DFS) and toxicity.

Results:

From 2018 to 2022, a total of 64 patients were included in the trial. Of these patients, 3 never started treatment and another patient was later found to have a metastasis of esophagus carcinoma. Therefore 60 patients were analyzed. Fifty-one patients had NSCLC, 8 patients had SCLC and only 1 patient had no histological confirmation of lung cancer. The median interval between the last thoracic radiotherapy and the diagnosis of relapse was 23.0 months (IQR 12.7-54.2 months). The median prescribed dose of the first radiotherapy was 68Gy EQD 2,10 (IQR 61 96Gy EQD 2,10 ). As reirradiation technique, 38 patients were treated with conventional fractionated radiotherapy (median prescribed dose: 60Gy EQD 2,10 ) and 22 with SBRT (median dose: prescribed 77Gy EQD 2,10 ). In 50 patients, the current PTV overlapped with the previous PTV. For other patient-, tumor- and treatment characteristics, see Table 1.

Table 1 - Patient-, tumor- and treatment characteristics

Characteristics

Number patients (%) or median (IQR)

Gender

Male

30 (50%)

Female

30 (50%)

KPS

100 - 90

23 (39%)

80

29 (48%)

70

8 (13%)

68 (64-75)

Median age (years)

Median CIRS

4 (2-5)

Median FEV 1 (%)

69 (56-84)

Stage (UICC)

I

24 (40%)

II

11 (18%)

III

22 (36%)

IV

3 (5%)

Location

Upper-middle lobe

40 (66.7)

Lower lobe

12 (20.0)

Mediastinum

8 (13.3)

Systemic therapy